---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-22-006850"
form_type: "8-K"
ticker: "XBIO"
cik: "0001534525"
company_name: "Xenetic Biosciences, Inc."
filed_at: "2022-10-12T23:59:59+00:00"
generated_at: "2026-06-23T04:04:55.007851+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Xenetic Biosciences issues 850,000 shares to CLS Therapeutics for patent rights

## Summary
- Issued 850,000 common shares to CLS Therapeutics LLC as consideration for assignment of certain patent rights.
- Transaction closed on October 12, 2022; shares unregistered and sold under Section 4(a)(2) and Regulation D.
- CLS represented itself as an accredited investor; shares restricted and not registered under Securities Act.
- No other securities or cash consideration disclosed; shares issued directly for patent asset acquisition.

## SEC filing metadata
- accession: 0001683168-22-006850
- form_type: 8-K
- ticker: XBIO
- cik: 0001534525
- company_name: Xenetic Biosciences, Inc.
- filed_at: 2022-10-12T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534525/000168316822006850/0001683168-22-006850-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534525/000168316822006850/xenetic_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-22-006850
- JSON: https://secwatch.observer/filing/0001683168-22-006850.json
- Plain text: https://secwatch.observer/filing/0001683168-22-006850.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.